Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.

The present disclosure provides isolated monoclonal antibodies or antigen-binding portions thereof that specifically bind to CD47 preferably human CD47 with high affinity, and can enhance tumor-targeting immune response by therapeutically boosting the phagocytic function of macrophage for cancer treatment. The disclosure also provides antibodies that are chimeric, humanized, bispecific, derivatized, single chain antibodies or portions of fusion proteins. Nucleic acid molecules encoding the antibodies of the disclosed invention and hybridoma are also provided. Pharmaceutical compositions comprising the antibodies of the disclosed invention are also provided. This disclosure also provides methods for regulating innate immune responses, as well as methods for treating cancer using an anti-CD47 antagonist antibody of the disclosed invention.

Provided are a human PD-1 antibody, an antigen-binding fragment thereof and a medical use thereof. A chimeric antibody containing a complementarity determining region (CDR) of the antibody, a pharmaceutical composition containing the human PD-1 antibody and the antigen-binding fragment thereof, and a use of the antibody in preparation of a drug for treating a disease or a disorder are further disclosed.

Provided are anti-AREG antibodies or immunoreactive fragments thereof for the treatment, diagnosis or prophylaxis of fibrotic diseases, including but not limited to renal fibrosis, hepatic fibrosis, pulmonary fibrosis, in particular, IPF. Polynucleotides or nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for making the antibodies are also provided. The anti-AREG antibodies specifically bind to AREG and block the function of AREG, through binding residues that locate in the EGF like domain.

Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and methods of using such antibodies to restore T-cell function in T-cells exhibiting T-cell exhaustion or T-cell anergy.

The present disclosure relates to antibodies or fragments thereof that target at least one conformational epitope of a Notch 3 or mutant Notch 3 receptor; and compositions and methods of use thereof.

There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain comprising three complementarity determining regions (CDR1-CDR3) and four framework regions, wherein: (a) at least one lysine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue, and/or (b) at least one arginine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue; wherein the polypeptide has increased intestinal stability relative to a corresponding polypeptide not having said histidine substitutions.

This invention relates to an adjuvant composition containing at least one binding molecule for neutralizing influenza virus and a vaccine composition containing the same. The composition containing at least one binding molecule for neutralizing influenza virus is capable of increasing the effects of a vaccine, and can thus be used as an adjuvant, which increases an immune response upon vaccine administration, and is very useful in the prevention of diseases caused by viruses.

Described herein are compositions and methods relating to LAP-binding agents, including, for example, anti-LAP antibodies, and to their use in methods of treatment of cancer. LAP-binding agents affected both systemic and intra-tumor immunity and were shown effective to treat a broad spectrum of cancer types.

The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA4.